Drugs & Aging

, Volume 22, Issue 7, pp 589–603 | Cite as

Dysregulation of T-Cell Function in the Elderly

Scientific Basis and Clinical Implications
  • Tamas Fulop
  • Anis Larbi
  • Anders Wikby
  • Eugenio Mocchegiani
  • Katsuiku Hirokawa
  • Graham Pawelec
Review Article

Abstract

The function of the immune system is to maintain body integrity by defending against infections, cancers, autoimmune diseases and inflammation-related chronic diseases. The immune response is known to become defective with aging, leading to decreased longevity and appearance of age-related disease. The most important changes occur in T-cell immunity, and are manifested particularly as altered clonal expansion of cells of limited antigen specificity. The causes of these alterations are multifactorial, and include thymic involution, T-cell subset changes and signal transduction alterations. The clinical consequences of these changes are not well defined, except for their extremely important negative impact on defence against infections, especially by new pathogens, and decreased responses to vaccination. Considering the public health consequences of decreased immune competence in old age, strategies for immune response modulation are desirable to decrease the health burden for the elderly and improve their quality of life.

References

  1. 1.
    Parker LC, Whyte MKB, Dower SK, et al. The expression and roles of toll-like receptors in the biology of the human neutro-phil. J Leukoc Biol 2005; 77: 1–7CrossRefGoogle Scholar
  2. 2.
    Gavazzi G, Krauze KH. Ageing and infection. Lancet Infect Dis 2002; 2: 659–66PubMedCrossRefGoogle Scholar
  3. 3.
    Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31: 578–85PubMedCrossRefGoogle Scholar
  4. 4.
    DeVeale B, Brummer T, Seroude L. Immunity and aging: the enemy within? Aging Cell 2004; 3: 195–208PubMedCrossRefGoogle Scholar
  5. 5.
    Wick G, Jansen-Dürr P, Berger P, et al. Diseases of aging. Vaccine 2000; 18: 1567–83PubMedCrossRefGoogle Scholar
  6. 6.
    Grubeck-Loebenstein B, Wick G. The aging of the immune system. Annu Rev Immunol 2002; 80: 248–90Google Scholar
  7. 7.
    Hirokawa K, Utsuyama M, Kasai M, et al. Understanding the mechanism of age-change of thymic function to promote T-cell differentiation. Immunol Lett 1994; 40: 269–77PubMedCrossRefGoogle Scholar
  8. 8.
    Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. Blood 2000; 95: 2860–8PubMedGoogle Scholar
  9. 9.
    Hirokawa K, Utsuyama M. Combined grafting of bone marrow and thymus, and sequential multiple thymus grafting in various strains of mice: the effect on immune functions and life span. Mech Ageing Dev 1989; 49: 49–60PubMedCrossRefGoogle Scholar
  10. 10.
    Mocchegiani E, Giacconi R, Cipriano C, et al. The variations during the circadian cycle of liver CD Id-unrestricted NK1.1+TCR gamma/delta+ cells lead to successful ageing: role of metallothionein/IL-6/gpl30/PARP-l interplay in very old mice. Exp Gerontol 2004; 39: 775–88PubMedCrossRefGoogle Scholar
  11. 11.
    Pawelec G, Akbar A, Caruso C, et al. Is immunosenescence infectious? Trends Immunol 2004; 25: 406–10PubMedCrossRefGoogle Scholar
  12. 12.
    Looney RJ, Falsey A, Campbell D, et al. Role of cytome-galovirus in the T cell changes seen in elderly individuals. Clin Immunol 1999; 90: 213–9PubMedCrossRefGoogle Scholar
  13. 13.
    Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379–85PubMedCrossRefGoogle Scholar
  14. 14.
    Effros RB, Boucher N, Porter V, et al. Decline in CD28- T cells in centenarians and in long-term cell cultures: a possible cause for both in vivo and vitro immunosenescence. Exp Gerontol 1994; 29: 601–9PubMedCrossRefGoogle Scholar
  15. 15.
    Effros RB, Pawelec G. Replicative senescence of T lymphocytes: does the Hayflick limit lead to immune exhaustion? Immunol Today 1997; 18: 450–4PubMedCrossRefGoogle Scholar
  16. 16.
    Franceschi C, Bonafé M, Valensin S, et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244–54PubMedCrossRefGoogle Scholar
  17. 17.
    Franceschi C, Bonafé M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clo-notypic immunity, and the filling of immunological space. Vaccine 2000; 18: 1717–20PubMedCrossRefGoogle Scholar
  18. 18.
    Spaulding C, Guo W, Effros RB, et al. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen specific proliferation. Exp Gerontol 1999; 34: 633–44PubMedCrossRefGoogle Scholar
  19. 19.
    Pawelec G, Sansom D, Rehbein A, et al. Decreased proliferative capacity and increased susceptibility to activation induced cell death in late passage human CD4+TCR2+ cultured T cell clones. Exp Gerontol 1996; 31: 655–68PubMedCrossRefGoogle Scholar
  20. 20.
    Mocchegiani E, Malavolta M. NK and NKT cell functions in immunosenescence. Aging Cell 2004; 3: 177–84PubMedCrossRefGoogle Scholar
  21. 21.
    Pawelec G. Immunosenescence impact in the young as well as the old. Mech Age Dev 1999; 108: 1–7CrossRefGoogle Scholar
  22. 22.
    Hirokawa K. Immunity and aging. In: Pathy MSJ, editor. Principles and practice of geriatric medicine. 3rd ed. New York: John Wiley and Sons, 1998: 35–47Google Scholar
  23. 23.
    O’Mahony L, Holland J, Jackson J, et al. Quantitative intracellu-lar cytokine measurement: age-related changes in proinflam-matory cytokine production. Clin Exp Immunol 1998; 113: 213–9PubMedCrossRefGoogle Scholar
  24. 24.
    Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovisrus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination: an impact of immunosenescence. Vaccine 2003; 21: 3826–36PubMedCrossRefGoogle Scholar
  25. 25.
    Baggio G, Donazzan S, Monti D, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12: 433–7PubMedGoogle Scholar
  26. 26.
    Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47: 639–46PubMedGoogle Scholar
  27. 27.
    Cohen HJ, Piper CS, Harris T. Markers of inflammation and coagulation predict decline in function and mortality in community dwelling elderly. J Am Geriatr Soc 2001; S1: A3–A10Google Scholar
  28. 28.
    Franceschi C, Bonafé M. Centenarians as a model for healthy aging. Biochem Soc Trans 2001; 31: 457–61CrossRefGoogle Scholar
  29. 29.
    Bonafé M, Olivieri F, Cavallone L, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31: 2357–61PubMedCrossRefGoogle Scholar
  30. 30.
    Murasko D, Gardner EM. Immunology of aging. In: Hazzard WR, Blass JP, Halter JB, et al, editors. Principles of geriatric medicine and gerontology. New York: McGraw-Hill, 2003: 35–52Google Scholar
  31. 31.
    Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. Annu Rev Immunol 2001; 19: 375–96PubMedCrossRefGoogle Scholar
  32. 32.
    Plackett TP, Boehmer ED, Faunce DE, et al. Aging and innate immune cells. J Leukoc Biol 2004; 76: 291–9PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia GG, Miller RA. Age-dependent defects in TCR-trig-gered cytoskeletal rearrangement in CD4+ T cells. J Immunol 2002; 169: 5021–7PubMedGoogle Scholar
  34. 34.
    Fulop T, Larbi A, Douziech N, et al. Signal transduction and functional changes in neutrophils with aging. Aging Cell 2004; 3: 217–26PubMedCrossRefGoogle Scholar
  35. 35.
    Nel AE, Slaughter N. T-cell activation through the antigen receptor: Part 2: role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immu-notherapy. J Allergy Clin Immunol 2002; 109: 901–15PubMedCrossRefGoogle Scholar
  36. 36.
    Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003; 3: 544–56PubMedCrossRefGoogle Scholar
  37. 37.
    Laude AJ, Prior IA. Plasma membrane microdomains: organization, function and trafficking. Mol Membr Biol 2004; 21: 193–205PubMedCrossRefGoogle Scholar
  38. 38.
    Taner SB, Onfelt B, Pirinen NJ, et al. Control of immune responses by trafficking cell surface proteins, vesicles and lipid rafts to and from the immunological synapse. Traffic 2004; 5: 651–61PubMedCrossRefGoogle Scholar
  39. 39.
    Pawelec G, Hirokawa K, Fulop T. T cell signalling with aging. Mech Ageing Dev 2001; 122: 1613–37PubMedCrossRefGoogle Scholar
  40. 40.
    Larbi A, Douziech N, Dupuis G, et al. Age-associated alterations in the recruitment of signal transduction proteins to lipid rafts in human T lymphocytes. J Leukoc Biol 2004; 75: 373–81PubMedCrossRefGoogle Scholar
  41. 41.
    Lesourd BM. Immune response during disease and recovery in the elderly. Proc Nutr Soc 1999; 58: 85–98PubMedCrossRefGoogle Scholar
  42. 42.
    Lesourd BM. Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Am J Clin Nutr 1997; 66: 478S–84SPubMedGoogle Scholar
  43. 43.
    Corman LC. The relationship between nutrition, infection and immunity. Med Clin North Am 1985; 69: 519–31PubMedGoogle Scholar
  44. 44.
    Sullivan DH, Sun S, Wals RC. Protein-energy malnutrition among elderly hospitalized patients: a prospective study. JAMA 1999; 281: 2013–9PubMedCrossRefGoogle Scholar
  45. 45.
    Chandra RK. The relation between immunology, nutrition and disease in the elderly people. Age Ageing 1990; 19: S25–31PubMedCrossRefGoogle Scholar
  46. 46.
    High KP. Nutritional strategies to boost immunity and prevent infections in the elderly individuals. Clin Infect Dis 2001; 33: 1892–900PubMedCrossRefGoogle Scholar
  47. 47.
    Mocchegiani E, Muzzioli M, Giacconi R. Zinc, metallothioneins, immune responses, survival and ageing. Biogerontology 2000; 1: 133–43PubMedCrossRefGoogle Scholar
  48. 48.
    Mocchegiani E, Giacconi R, Muzzioli M, et al. Zinc, infections and immunosenescence. Mech Ageing Dev 2000; 121: 21–35PubMedCrossRefGoogle Scholar
  49. 49.
    Bruunsgaard H, Skinboj P, Qvist J, et al. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis 1999; 180: 551–4PubMedCrossRefGoogle Scholar
  50. 50.
    Krabbe KS, Bruunsgaard H, Hanson CM, et al. Aging is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 2001; 8: 333–8PubMedGoogle Scholar
  51. 51.
    Arlt W, Hewison M. Hormones and immune function: implications of aging. Aging Cell 2004; 3: 209–16PubMedCrossRefGoogle Scholar
  52. 52.
    Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298–300PubMedCrossRefGoogle Scholar
  53. 53.
    Burns EA, Goodwin JS. Immunodeficiency and aging. Drugs Aging 1997; 11: 374–97PubMedCrossRefGoogle Scholar
  54. 54.
    Pahlavani MA, Harris MD. Effect of in vitro generation of oxygen free radicals on T cell function in young and old rats. Free Radic Biol Med 1998; 25: 903–13PubMedCrossRefGoogle Scholar
  55. 55.
    Wikby A, Johansson B, Ferguson F, et al. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 1994; 29: 531–41PubMedCrossRefGoogle Scholar
  56. 56.
    Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28() T cell clonal expansions and an imbalance in the production of Thl and Th2 cytokines. J Immunol 2002; 168: 5893–9PubMedGoogle Scholar
  57. 57.
    Goronzy JJ, Fulbright JW, Crowson CS, et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182–7PubMedCrossRefGoogle Scholar
  58. 58.
    Nilsson B-O, Ernerudh J, Johansson B, et al. Morbidity does not influence the T-cell immune risk phenotype in the elderly: findings in the Swedish NONA Immune Study using sample selection protocols. Mech Ageing Dev 2003; 124: 469–76PubMedCrossRefGoogle Scholar
  59. 59.
    Ferguson FG, Wikby A, Maxson P, et al. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and non survivors. J Gerontol A Biol Sci Med Sci 1995; 50: B378–82PubMedCrossRefGoogle Scholar
  60. 60.
    Olsson J, Wikby A, Johannson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121: 187–201PubMedCrossRefGoogle Scholar
  61. 61.
    Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 2000; 30: 931–3PubMedCrossRefGoogle Scholar
  62. 62.
    Mocchegiani E, Muzzioli M, Giacconi R, et al. Metallothioneins/PARP-l/IL-6 interplay on natural killer cell activity in elderly. Parallelism with nonagenarians and old infected humans: effect of zinc supply. Mech Ageing Dev 2003; 124: 459–68PubMedCrossRefGoogle Scholar
  63. 63.
    Mocchegiani E, Muzzioli M. Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J Nutr 2000; 130: 1424S–31SPubMedGoogle Scholar
  64. 64.
    Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996; 14: 836–9PubMedCrossRefGoogle Scholar
  65. 65.
    Balducci L. Anemia, cancer, and aging. Cancer Control 2003; 10: 478–86PubMedGoogle Scholar
  66. 66.
    Bonafé M, Valensin S, Gianni W, et al. The unexpected contribution of immunosenescence to the leveling off of cancer incidence and mortality in the oldest old. Crit Rev Oncol Hematol 2001; 39: 227–33PubMedCrossRefGoogle Scholar
  67. 67.
    Fraumeni Jr JF, Hoover R. Immunosurveillance and cancer: epidemiologic observations. Natl Cancer Inst Monogr 1977; 47: 121–6PubMedGoogle Scholar
  68. 68.
    Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107–11PubMedCrossRefGoogle Scholar
  69. 69.
    Panossian L, Porter VR, Valenzuela HF, et al. Telomere shortening in T cells correlates with Alzheimer’s disease status. Neurobiol Aging 2003; 24: 77–84PubMedCrossRefGoogle Scholar
  70. 70.
    Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203–13PubMedCrossRefGoogle Scholar
  71. 71.
    Blasko I, Marx F, Steiner E, et al. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63–8PubMedGoogle Scholar
  72. 72.
    Barger SW, Hörster D, Furukawa K, et al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta peptide toxicity: evidence for involvement of a kappa-B binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995; 92: 9328–32PubMedCrossRefGoogle Scholar
  73. 73.
    Blasko I, Schmitt TL, Steiner I, et al. Tumor necrosis factor alpha augments amyloid beta protein (25–35) induced apoptosis in human cells. Neurosci Lett 1997; 238: 17–20PubMedCrossRefGoogle Scholar
  74. 74.
    Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer disease brain. Neuroscience 1998; 87: 319–24PubMedCrossRefGoogle Scholar
  75. 75.
    Jonasson L, Tompa A, Wikby A. Expansion of peripheral CD8+ T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med 2003; 254: 472–8PubMedCrossRefGoogle Scholar
  76. 76.
    Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361–403PubMedCrossRefGoogle Scholar
  77. 77.
    Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344–50PubMedCrossRefGoogle Scholar
  78. 78.
    Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol 2001; 22: 665–9PubMedCrossRefGoogle Scholar
  79. 79.
    Lusis AJ. Atherosclerosis. Nature 2000; 407: 233–41PubMedCrossRefGoogle Scholar
  80. 80.
    Hansson GK, Seifert PS, Olsson G, et al. Immunohistochemical detection of macrophages and T lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1991; 11: 745–50CrossRefGoogle Scholar
  81. 81.
    Wick G, Scett G, Amberger A, et al. Is athersoclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27–33PubMedCrossRefGoogle Scholar
  82. 82.
    Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–74PubMedCrossRefGoogle Scholar
  83. 83.
    Goavert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1999; 272: 1661–5Google Scholar
  84. 84.
    Fulop T, Wagner JR, Khalil A, et al. Relationship between response to influenza vaccination and the nutritional status in institutionalized elderly subjects. J Gerontol 1999; 54A: M59–64Google Scholar
  85. 85.
    Nichol KL, Wuorenma I, von Sternberg T. Benefits of influenza vaccination for low-, intermediate- and high-risk senior citizens. Arch Intern Med 1998; 158: 1769–76PubMedCrossRefGoogle Scholar
  86. 86.
    Guebre-Xabier M, Hammond SA, Ellingsworth LR. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol 2004; 78: 7610–8PubMedCrossRefGoogle Scholar
  87. 87.
    Langkamp-Henken B, Bender BS, Gardner EM, et al. Nutritional formula enhanced immune function and reduced days of symptoms of upper respiratory tract infection in seniors. J Am Geriatr Soc 2004; 52: 3–12PubMedCrossRefGoogle Scholar
  88. 88.
    Utsuyama M, Ichikawa M, Konno-Shirakawa A, et al. Retardation of the age-associated decline of immune functions in aging rats under dietary restriction and daily physical exercise. Mech Ageing Dev 1996; 91: 219–28PubMedCrossRefGoogle Scholar
  89. 89.
    Autran B, Carcelain G, Combadiere B, et al. Therapeutic vaccines for chronic infections. Science 2004; 305: 205–8PubMedCrossRefGoogle Scholar
  90. 90.
    Franceschi C, Valensin S, Lescai F, et al. Neuroinflammation and the genetics of Alzheimer’s disease: the search for a proinflammatory phenotype. Aging (Milano) 2001; 13: 163–70Google Scholar
  91. 91.
    Kovacs EJ, Plackett TP, Witte PL. Estrogen replacement, aging, and cell-mediated immunity after injury. J Leukoc Biol 2004; 76: 36–41PubMedCrossRefGoogle Scholar
  92. 92.
    Anversa P, Leri A, Kajstura J, et al. Myocyte growth and cardiac repair. Mol Cell Cardiol 2002; 34: 91–105CrossRefGoogle Scholar
  93. 93.
    Bagnara GP, Bonsi L, Strippoli P, et al. Hemopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. J Gerontol 2000; 55: B67–70CrossRefGoogle Scholar
  94. 94.
    Aspinall R, Andrew D, Pido-Lopez J. Age-associated changes in thymopoiesis. Springer Semin Immunopathol 2002; 24: 87–101PubMedCrossRefGoogle Scholar
  95. 95.
    Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664–75PubMedGoogle Scholar
  96. 96.
    Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200–5PubMedCrossRefGoogle Scholar
  97. 97.
    Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(in+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823–32PubMedCrossRefGoogle Scholar
  98. 98.
    Mocchegiani E, Straub RH. Possible new anti-aging strategies related to neuroendocrine-immune interactions. In: Straub RH, Mocchegiani E, editors. The neuroendocrine immune network in aging. Neuroimmune biology. Vol 4. Amsterdam: Elsevier, 2004: 399–409Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Tamas Fulop
    • 1
  • Anis Larbi
    • 1
  • Anders Wikby
    • 2
  • Eugenio Mocchegiani
    • 3
  • Katsuiku Hirokawa
    • 4
  • Graham Pawelec
    • 5
  1. 1.Immunology Program, Geriatric Division, Research Center on Aging, Faculty of MedicineUniversity of SherbrookeSherbrookeCanada
  2. 2.Department of Natural Science and Biomedicine, School of Health SciencesJönköping UniversityJönköpingSweden
  3. 3.Section Nutrition, Immunology Center, Immunity and Ageing, Research DepartmentItalian National Research Centres on AgeingAnconaItaly
  4. 4.Departments of Pathology and Immunology, Ageing and Developmental SciencesTokyo Medical and Dental University Graduate School, Bunkyo-kuTokyoJapan
  5. 5.Section for Transplantation Immunology and Immunohaematology, Second Department of Internal Medicine, Tübingen Ageing and Tumour Immunology GroupUniversity of Tübingen Medical School, Zentrum für Medizinsche ForschungTübingenGermany

Personalised recommendations